Compare up to 4 stocks side by side, across all 7 of StockIQ's scoring categories.
| Category | RANI Rani Therapeutics Holdings, Inc. | AAPG Ascentage Pharma Group International - American Depository |
|---|---|---|
| Price | $0.79 -1.1% | $16.31 +6.3% |
| StockIQ Score | 44D Weak Risk: Medium | 42D Weak Risk: Medium |
| Technical | 18F | 36F |
| Fundamental | 29F | 35F |
| Growth | 76B+ | 50C- |
| Fair Value | 55C | 38F |
| News | 50C- | 50C- |
| Quality | 63C+ | 50C- |
| Risk | 46D+ | 48D+ |
Scores are based on real financial data only and do not constitute investment advice. How the score is calculated
Rani Therapeutics (RANI) outperforms Ascentage Pharma (AAPG) in growth (76 vs. 50) and valuation (55 vs. 38), showing stronger potential expansion and pricing relative to its fundamentals. However, AAPG scores higher in technicals (36 vs. 18) and fundamentals (35 vs. 29), indicating more stable trading patterns and stronger core business health. Both carry a "WEAK" rating, but RANI’s growth edge may appeal to investors prioritizing future potential.
